Literature DB >> 15024394

Antipsychotic drugs antagonize human serotonin type 3 receptor currents in a noncompetitive manner.

G Rammes1, B Eisensamer, U Ferrari, M Shapa, G Gimpl, K Gilling, C Parsons, K Riering, G Hapfelmeier, B Bondy, W Zieglgänsberger, F Holsboer, R Rupprecht.   

Abstract

The serotonin type 3 (5-HT(3)) receptor is the only ligand-gated ion channel receptor for serotonin (5-HT). 5-HT(3) receptors play an important role in modulating the inhibitory action of dopamine in mesocorticolimbic brain regions. Neuroleptic drugs are commonly thought to exert their psychopharmacological action mainly through dopamine and serotonin type 2 (5-HT(2)) receptors. Except for clozapine, a direct pharmacological interaction of neuroleptics with 5-HT(3) receptors has not yet been described. Using the concentration-clamp technique, we investigated the effects of flupentixol, various phenothiazines, haloperidol, clozapine and risperidone on Na(+)-inward currents through 5-HT(3) receptors stably expressed in human embryonic kidney 293 cells, and through endogenous 5-HT(3) receptors of murine N1E-115 neuroblastoma cells. In addition, we studied their effects on Ca(2+) influx, measured as a change in intracellular Ca(2+) concentrations ([Ca(2+)](i)). All neuroleptic drugs, but not risperidone, antagonized Na(+)- and Ca(2+)-inward currents evoked by 5-HT (10 microM for 2 s and 1 microM, respectively) in a voltage-independent manner. Only clozapine was a competitive antagonist, while all other compounds turned out to be noncompetitive. Fluphenazine and haloperidol affected membrane anisotropy at concentrations below their IC(50) values, indicating that a change in membrane anisotropy might contribute to their antagonistic effect at the 5-HT(3) receptor. Only structure analogues of flupentixol and fluphenazine with a lipophilic side chain were potent antagonists against 5-HT-evoked Na(+) and Ca(2+) currents. Since 5-HT(3) receptors modulate mesolimbic and mesocortical dopaminergic activity, the functional antagonism of neuroleptics at 5-HT(3) receptors may contribute to their antipsychotic efficacy and may constitute a not yet recognized pharmacological principle of these drugs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15024394     DOI: 10.1038/sj.mp.4001490

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  20 in total

Review 1.  Modulation of ligand-gated ion channels by antidepressants and antipsychotics.

Authors:  Gerhard Rammes; Rainer Rupprecht
Journal:  Mol Neurobiol       Date:  2007-04       Impact factor: 5.590

Review 2.  Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission.

Authors:  K D Alex; E A Pehek
Journal:  Pharmacol Ther       Date:  2006-10-17       Impact factor: 12.310

3.  Molecular mechanisms of serotonergic action of the HIV-1 antiretroviral efavirenz.

Authors:  Dhwanil A Dalwadi; Seongcheol Kim; Shahnawaz M Amdani; Zhenglan Chen; Ren-Qi Huang; John A Schetz
Journal:  Pharmacol Res       Date:  2016-05-06       Impact factor: 7.658

Review 4.  Allosteric modulation of the 5-HT(3) receptor.

Authors:  Paul A Davies
Journal:  Curr Opin Pharmacol       Date:  2011-02-20       Impact factor: 5.547

Review 5.  The 5-HT3 receptor as a therapeutic target.

Authors:  Andrew J Thompson; Sarah C R Lummis
Journal:  Expert Opin Ther Targets       Date:  2007-04       Impact factor: 6.902

6.  Association Study of Serotonin 3 Receptor Subunit Gene Variants in Antipsychotic-Induced Weight Gain.

Authors:  Clement C Zai; Arun K Tiwari; Nabilah I Chowdhury; Eva J Brandl; Sajid A Shaikh; Natalie Freeman; Jeffrey A Lieberman; Herbert Y Meltzer; James L Kennedy; Daniel J Müller
Journal:  Neuropsychobiology       Date:  2017-05-23       Impact factor: 2.328

7.  Impact of lipid raft integrity on 5-HT3 receptor function and its modulation by antidepressants.

Authors:  Caroline Nothdurfter; Sascha Tanasic; Barbara Di Benedetto; Gerhard Rammes; Eva-Maria Wagner; Thomas Kirmeier; Vanessa Ganal; Julia S Kessler; Theo Rein; Florian Holsboer; Rainer Rupprecht
Journal:  Neuropsychopharmacology       Date:  2010-03-03       Impact factor: 7.853

8.  The alpha-7 nicotinic receptor partial agonist/5-HT3 antagonist RG3487 enhances cortical and hippocampal dopamine and acetylcholine release.

Authors:  Mei Huang; Anna R Felix; Sunoh Kwon; David Lowe; Tanya Wallace; Luca Santarelli; Herbert Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  2013-12-07       Impact factor: 4.530

Review 9.  5-HT3 receptors.

Authors:  A J Thompson; S C R Lummis
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

10.  Pharmacodynamics of memantine: an update.

Authors:  G Rammes; W Danysz; C G Parsons
Journal:  Curr Neuropharmacol       Date:  2008-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.